Rhopressa fda approval history drugs com?

What is Rhopressa, and when did the FDA approve it?

Rhopressa is the brand name for netarsudil ophthalmic solution, used to lower intraocular pressure in glaucoma and ocular hypertension. The FDA approval history for Rhopressa includes the initial approval for its glaucoma/ocular hypertension indication and any subsequent labeling or review milestones listed on Drugs.com’s approval-history pages.

To see the exact approval date(s), application number, and related FDA status items as they appear on Drugs.com, use this Drugs.com page: Rhopressa (netarsudil) FDA approval history

What does the Drugs.com “approval history” page usually include?

On Drugs.com, an “FDA approval history” page typically lists the drug’s FDA review/approval timeline items such as the approval date and official labeling history entries tied to the FDA’s approval process. For Rhopressa, the page above is the direct source for those date-specific details.

Are there other FDA-related timeline details besides approval date?

Depending on what Drugs.com has captured for Rhopressa, the approval-history page may reflect FDA actions beyond the first approval (for example, changes tied to labeling updates). The authoritative, date-by-date items for Rhopressa are the ones shown on the Drugs.com page linked above.

Related sources you may want to check

If you’re also tracking IP/exclusivity or patent-driven exclusivity timelines for netarsudil/Rhopressa, DrugPatentWatch can help: DrugPatentWatch search for Rhopressa / netarsudil